Login to Your Account



Too-Short Needles To Blame?

Peramivir Stumbles In Phase II Influenza Study; BioCryst Falls

By Jennifer Boggs


Friday, September 21, 2007
Shares of BioCryst Pharmaceuticals Inc. tumbled more than 30 percent following a Phase II miss with the influenza drug peramivir, despite assurances from company executives that inadequate needle-lengths were to blame. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription